Pure Global
NCT06376851

AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management

DECIDE Registry: AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management
HeartFlow, Inc.·ClinicalTrials.gov·diagnostic testEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Coronary Artery Disease
Drug/Device/Intervention
AI-enabled quantitative coronary plaque analysis (AI-QCPA)
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
HeartFlow, Inc.
Location
Greensboro, United States of America
Timeline & enrollment
Phase
N/A
Start date
Mar 27, 2024
End date
Mar 27, 2030
Enrollment
10000 participants
Primary outcome

Primary Endpoint

Summary

The objective of HeartFlow's DECIDE Registry is to collect observational data about the
 management of patients before and after HeartFlow Artificial Intelligence-Quantitative
 Coronary Plaque Analysis (AI-QCPA).

ICD-10 classifications
Cardiovascular disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart diseaseAbnormal findings on diagnostic imaging of heart and coronary circulationCoronary vasodilators, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06376851
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06376851 through Pure Global AI's free database. This phase not specified trial is sponsored by HeartFlow, Inc. and is currently Enrolling by invitation. The study focuses on Coronary Artery Disease. Target enrollment is 10000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.